UMMS Affiliation

Department of Medicine, Division of Gastroenterology

Publication Date


Document Type



Chemicals and Drugs | Medicinal Chemistry and Pharmaceutics | Pharmacy and Pharmaceutical Sciences


BACKGROUND: Parenteral nutrition is often a mandatory therapeutic strategy for cases of septicemia. Likewise, therapeutic application of anti-oxidants, anti-inflammatory therapy, and endotoxin lowering, by removal or inactivation, might be beneficial to ameliorate the systemic inflammatory response during the acute phases of critical illness. Concerning anti-inflammatory properties in this setting, omega-3 fatty acids of marine origin have been frequently described. This study investigated the anti-inflammatory and LPS-inactivating properties of krill oil (KO)-in-water emulsion in human macrophages in vitro.

MATERIALS AND METHODS: Differentiated THP-1 macrophages were activated using specific ultrapure-LPS that binds only on the toll-like receptor 4 (TLR4) in order to determine the inhibitory properties of the KO emulsion on the LPS-binding capacity, and the subsequent release of TNF-alpha.

RESULTS: KO emulsion inhibited the macrophage binding of LPS to the TLR4 by 50% (at 12.5 microg/mL) and 75% (at 25 microg/mL), whereas, at 50 microg/mL, completely abolished the LPS binding. Moreover, KO (12.5 microg/mL, 25 microg/mL, or 50 microg/mL) also inhibited (30%, 40%, or 75%, respectively) the TNF-alpha release after activation with 0.01 microg/mL LPS in comparison with LPS treatment alone.

CONCLUSION: KO emulsion influences the LPS-induced pro-inflammatory activation of macrophages, possibly due to inactivation of the LPS binding capacity.


LPS, cytokines, krill oil-in-water emulsion, omega-3 fatty acids, phospholipids, septic shock

Rights and Permissions

Copyright © 2017 by the authors.

DOI of Published Version



Mar Drugs. 2017 Mar 15;15(3). pii: E74. doi: 10.3390/md15030074. Link to article on publisher's site

Journal/Book/Conference Title

Marine drugs

Related Resources

Link to Article in PubMed

PubMed ID


Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.